Maternal methadone dose, placental methadone concentrations, and neonatal outcomes

Clinical Chemistry

Volumn 57, Issue 3, 2011, Pages 449-458

  De Castro, Ana ^a,b   Jones, Hendreé E ^c   Johnson, Rolley E ^c,d   Gray, Teresa R ^a   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RECKITT BENCKISER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; BUPRENORPHINE; COCAINE; METHADONE; OPIATE;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EXPOSURE; FEMALE; HEAD CIRCUMFERENCE; HUMAN; MATERNAL SERUM; MATERNAL TREATMENT; MECONIUM; NEWBORN; PLACENTA; PREDICTION; PRENATAL EXPOSURE; QUANTITATIVE ANALYSIS; URINE LEVEL; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; APGAR SCORE; BIRTH WEIGHT; BODY SIZE; CEPHALOMETRY; COCAINE; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; MECONIUM; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTERS; PYRROLIDINES; TISSUE DISTRIBUTION;

EID: 79952240055     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.154864     Document Type: Article

References (34)

1. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004;43:487-514. (Pubitemid 38858303)
2. Ala-Kokko TI, Myllynen P, Vähäkangas K. Ex vivo perfusion of the human placenta cotyledone: implications for anesthetic pharmacology. Int J Obstet Anesth 2000;9:26-38.
3. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int 2002;128:20-30.
4. Strauss ME, Andresko M, Stryker JC, Wardell JN, Dunkel LD. Methadone maintenance during pregnancy: pregnancy, birth, and neonate characteristics. Am J Obstet Gynecol 1974;120:895-900.
5. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007;32:19-25. (Pubitemid 44908840)
6. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79:1-10. (Pubitemid 41557119)
7. de Castro A, Concheiro M, Shakleya DM, Huestis MA. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J Anal Toxicol 2009;33:243-52.
8. Choo RE, Murphy CM, Jones HE, Huestis MA. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3- diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:369-73. (Pubitemid 40091657)
9. Gray TR, Shakleya DM, Huestis MA. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem 2009;393:1977-90.
10. Lewis DE, inventor; Lewis DE, assignee. Forensically-acceptable determinations of gestational fetal exposure to drugs and other chemical agents. US Patent 5,532,131. 1996 Jul 2.
11. Choo RE, Huestis MA, Schroeder JR, Shin AS, Jones HE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75:253-60. (Pubitemid 38993295)
12. Nikolaou PD, Papoutsis II, Atta-Politou J, Athanaselis SA, Spiliopoulou CA, Calokerinos AC, Maravelias CP. Validated method for the simultaneous determination of methadone and its main metabolites (EDDP and EMDP) in plasma of umbilical cord blood by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;867:219-25.
13. Doberczak TM, Kandall SR, Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993;81:936-40. (Pubitemid 23168737)
14. Jansson LM, Choo RE, Harrow C, Velez M, Schroeder JR, Lowe R, Huestis MA. Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact 2007;23:184-90. (Pubitemid 46681153)
15. Quintela O, López P, Bermejo AM, López-Rivadulla M. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and alprazolam in human plasma by liquid chromatographyelectrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;834:188-94.
16. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL, Hankins GDV, Ahmed MS. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005;69:187-97. (Pubitemid 39592885)
17. Shakleya DM, Jansson LM, Huestis MA. Validation of a LC-APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:267-72. (Pubitemid 47302920)
18. Jansson LM, Choo R, Velz ML, Harrow C, Schroeder JR, Shakleya DM, Huestis MA. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008;121:106-14.
19. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL, Hankins GDV, Ahmed MS. Methadone metabolism by human placenta. Biochem Pharmacol 2004;68:583-91. (Pubitemid 38887440)
20. Ring JA, Ghabrial H, Ching MS, Smallwood RA, Morgan DJ. Fetal hepatic drug elimination. Pharmacol Ther 1999;84:429-45.
21. Strolin Benedetti M, Whomsley R, Baltes E. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:447-71.
22. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69. (Pubitemid 39221799)
23. Kuschel CA, Austerberry L, Cornwell M, Couch R, Rowley RSH. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004;89:F390-3.
24. Eap CB, Bourquin M, Martin JL, Spagnoli J, Livoti S, Powell K, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000;61:47-54.
25. Mack G, Thomas D, Giles W, Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health 1991;27:96-100.
26. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr 1976;88:1044-8.
27. Moore C, Negrusz A, Lewis D. Determination of drugs of abuse in meconium. J Chromatogr B Biomed Sci Appl 1998;713:137-46. (Pubitemid 28346483)
28. Kinsella JP. Meconium aspiration syndrome: Is surfactant lavage the answer? J Chromatogr B Analyt Technol Biomed Life Sci 2005;814:369-73.
29. Luck W, Nau H, Hansen R, Steldinger R. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther 1985;8:384-95. (Pubitemid 16204068)
30. Martin I, López-Vilchez MA, Mur A, García-Algar O, Rossi S, Marchei E, Pichini S. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther Drug Monit 2007;29:127-9. (Pubitemid 46279887)
31. García-Algar O, López-Vilchez MA, Martin I, Mur A, Pellegrini M, Pacifici R, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila) 2007;45:295-8. (Pubitemid 46525202)
32. García-Algar O, Vall O, Alameda F, Puig C, Pellegrini M, Pacifici R, Pichini S. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch Dis Child Fetal Neonatal Ed 2005; 90:F276-7.
33. Concheiro-Guisan M, Shakleya DM, Huestis MA. Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. Anal Bioanal Chem 2009;394:513-22.
34. Substance Abuse and Mental Health Services Administration. Department of Health and Human Services. Mandatory guidelines for federal workplace drug testing programs. Federal Register 2008;73:71858-907.